Jacob Chacko - 20 Jul 2022 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
20 Jul 2022
Net transactions value
$0
Form type
4
Filing time
21 Jul 2022, 16:05:48 UTC
Previous filing
25 May 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Disposed to Issuer -437,500 -100% 0 20 Jul 2022 Common Stock 437,500 $16.00 Direct F1, F2
transaction ORIC Stock Option (right to buy) Disposed to Issuer -280,000 -100% 0 20 Jul 2022 Common Stock 280,000 $29.83 Direct F2, F3
transaction ORIC Stock Option (right to buy) Disposed to Issuer -300,000 -100% 0 20 Jul 2022 Common Stock 300,000 $9.48 Direct F2, F4
transaction ORIC Stock Option (right to buy) Award +437,500 437,500 20 Jul 2022 Common Stock 437,500 $4.36 Direct F2, F5
transaction ORIC Stock Option (right to buy) Award +280,000 280,000 20 Jul 2022 Common Stock 280,000 $4.36 Direct F2, F6
transaction ORIC Stock Option (right to buy) Award +300,000 300,000 20 Jul 2022 Common Stock 300,000 $4.36 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter.
F2 On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share.
F3 Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter.
F4 Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter.
F5 One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter.
F6 Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.